Core Viewpoint - The announcement highlights that Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s subsidiary, Beijing Yiling Pharmaceutical Co., Ltd., has successfully negotiated to include its product, Qifang Bitong Pian, in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market promotion and sales scale [1][2]. Group 1: Product Inclusion in National Medical Insurance - Qifang Bitong Pian is a proprietary product developed by the company, classified as a Class 1 traditional Chinese medicine, specifically for treating persistent allergic rhinitis [1]. - The product has been assigned a medical insurance payment standard of 1.78 yuan per tablet, with a validity period for the agreement from January 1, 2026, to December 31, 2027 [1]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which received its drug registration certificate from the National Medical Products Administration in January 2025 [1]. Group 2: Impact on Company Operations - In addition to Qifang Bitong Pian, the company has 11 other proprietary products included in the National Medical Insurance Directory for 2025, which may enhance the company's market presence and sales [2]. - The inclusion of these 12 proprietary traditional Chinese medicine products in the insurance directory is expected to have a positive long-term impact on the company's operational development, although the short-term effects on financial performance are currently uncertain [2].

Core Viewpoint - Yiling Pharmaceutical has successfully included its innovative traditional Chinese medicine, Qifang Nasal Tablets, in the National Medical Insurance Directory, marking a significant recognition of the company's innovation value and responsibility in the healthcare sector [1] Group 1: Product Development and Approval - Qifang Nasal Tablets, approved for treating allergic rhinitis, is the fifth innovative traditional Chinese medicine from Yiling Pharmaceutical to be included in the National Medical Insurance Directory [1] - The drug has shown significant efficacy in clinical trials, with a total effective rate of 74.71% and a patient satisfaction improvement rate of 89% [2] - Yiling Pharmaceutical has a strong pipeline, with two new traditional Chinese medicines and one classic formula currently in the new drug application process [7] Group 2: Research and Development Investment - Yiling Pharmaceutical maintains a high level of R&D investment, with total expenditures of 895 million, 935 million, and 908 million yuan from 2022 to 2024, consistently ranking among the top in the traditional Chinese medicine industry [3] - The company has successfully launched five innovative traditional Chinese medicines in the past five years, all of which are included in the medical insurance directory [3] Group 3: Market Performance and Growth - The company has established a solid revenue base with major products like Tongxinluo, Rensong Yangxin, and Qilichangxin, each generating over 1 billion yuan in annual sales [6] - There is a notable rise in revenue contribution from secondary products, indicating a shift in the company's growth dynamics [5][6] - Yiling Pharmaceutical has maintained a steady rhythm of R&D, aiming to introduce 1-2 new products into clinical research and approval each year [6]

Core Viewpoint - The announcement highlights that Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd., has successfully negotiated to include its product Qifang Bitong Pian in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales scale for the company [1][2]. Group 1: Product Inclusion in National Medical Insurance - Qifang Bitong Pian is a proprietary product developed by the company, classified as a Class 1 traditional Chinese medicine, and is used for treating persistent allergic rhinitis [1]. - The product has been assigned a medical insurance payment standard of 1.78 yuan per tablet, with the agreement effective from January 1, 2026, to December 31, 2027 [1]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which received its drug registration certificate from the National Medical Products Administration in January 2025 [1]. Group 2: Impact on Company Operations - In addition to Qifang Bitong Pian, the company has 11 other proprietary products included in the National Medical Insurance Directory for 2025, which may positively influence the company's market promotion and sales growth [2]. - The inclusion of these 12 proprietary traditional Chinese medicine products in the insurance directory is expected to have a favorable long-term impact on the company's operational development, although the short-term effects on financial performance are currently uncertain [2].

证券日报网讯12月7日晚间，以岭药业（002603）发布公告称，公司全资子公司北京以岭药业有限公司 独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药品目录 (2025年)》。 ...

Core Viewpoint - Yiling Pharmaceutical's product Qifang Nizhong Pian has been included in the national medical insurance directory, marking a significant milestone for the company and the innovation of traditional Chinese medicine [1][3]. Group 1: Product and Innovation - Qifang Nizhong Pian is the first innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, filling a clinical gap [1][3]. - The product received approval from the National Medical Products Administration in January 2025 and was launched in Macau in July 2025, becoming the first innovative traditional Chinese medicine registered in Macau [3]. - The inclusion in the medical insurance directory is a recognition of the product's innovation, clinical efficacy, and safety, which will significantly enhance its accessibility and affordability [3]. Group 2: R&D Investment and Achievements - Yiling Pharmaceutical has maintained a high level of R&D investment, with R&D expenses reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of revenue [4]. - From 2019 to 2024, the company’s cumulative R&D investment exceeded 5 billion yuan, consistently leading the industry average [4]. - The company has developed 17 patented traditional Chinese medicines covering eight major clinical disease systems, with 12 products included in the national medical insurance directory and 5 in the national essential drug list [4]. Group 3: Future Prospects and Team Structure - Yiling Pharmaceutical has a robust pipeline of products, with several traditional Chinese medicines and chemical drugs at various stages of clinical research and application [5]. - The company has established a high-quality research and management team, recognized as part of Hebei Province's "Giant Plan" and awarded multiple national and provincial scientific achievement awards [5]. - The company’s commitment to innovation and quality control positions it as a benchmark enterprise in the pharmaceutical industry, driving the development of traditional Chinese medicine [6].

Core Viewpoint - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog was released, highlighting the importance of innovative drugs in reducing public burden and promoting high-quality development in the pharmaceutical industry [1][3]. Group 1: Policy and Industry Impact - The adjustment mechanism of the national medical insurance catalog is becoming more scientific and standardized, facilitating the rapid entry of innovative drugs into clinical use [3]. - The support for innovative drugs with high clinical value and significant patient benefits aligns with the government's focus on people-centered development [3][4]. Group 2: Company Innovations and Achievements - Yiling Pharmaceutical has established over 60 standardized Chinese medicinal herb cultivation bases to ensure quality from the source and has developed a comprehensive quality traceability system [4]. - The company has conducted over 40 evidence-based medical studies, with significant contributions to the field of traditional Chinese medicine, including four entries in the top ten medical research projects in 2024 [4]. Group 3: New Drug Approval - Yiling Pharmaceutical's Qifang Bitong Pian, a treatment for allergic rhinitis, has been approved for inclusion in the 2025 national medical insurance catalog, marking the company's fifth innovative traditional Chinese medicine to pass national negotiations [5][6]. - This drug is recognized as a Class 1.1 new drug and fills a clinical gap in the treatment of persistent allergic rhinitis [5].

Core Insights - Yiling Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yiling, has successfully negotiated for its exclusive product, Qifang Nasal Tablets, to be included in the National Medical Insurance Directory (2025 version) for the first time [1] - The drug is classified as a Category 1.1 traditional Chinese medicine, specifically for the treatment of persistent allergic rhinitis, with a reimbursement price set at 1.78 yuan per tablet, and the agreement is valid until December 31, 2027 [1] - In addition to Qifang Nasal Tablets, the company has 11 other exclusive products listed in the directory, which is expected to have a positive long-term impact on the company's operations, although the short-term impact on performance remains uncertain [1] Company Summary - Qifang Nasal Tablets have received registration approval from the National Medical Products Administration and a registration certificate for traditional Chinese medicine in Macau [1] - The inclusion of 12 products in the National Medical Insurance Directory is anticipated to enhance the company's long-term business prospects [1]

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Beijing Yiling, has successfully negotiated for its exclusive product, Qifang Nasal Tablets, to be included in the National Medical Insurance Directory (2025 edition) for the first time [1] Group 1: Company Developments - Yiling Pharmaceutical has a total of 12 exclusive products included in the National Medical Insurance Directory (2025 edition), which includes Qifang Nasal Tablets and other products such as Tongxinluo Tablets (Capsules), Ginseng and Pine Nut Heart Nourishing Capsules, and Lianhua Qingwen Tablets (Capsules, Granules) [1] - The inclusion of these products in the medical insurance directory is expected to enhance their market accessibility and potentially increase sales [1] Group 2: Industry Impact - The addition of Yiling Pharmaceutical's products to the National Medical Insurance Directory reflects a broader trend in the industry towards integrating traditional Chinese medicine into the national healthcare system [1] - This move may encourage other companies in the industry to seek similar negotiations for their products, potentially leading to increased competition and innovation within the sector [1]

证券代码：002603 证券简称：以岭药业 公告编号：2025-051 石家庄以岭药业股份有限公司 关于子公司药品通过谈判纳入《国家医保目录》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据国家医疗保障局网站于 2025 年 12 月 7 日发布的《关于印发<国家基本 医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录> （2025 年）的通知》（医保发【2025】33 号），石家庄以岭药业股份有限公司 （以下简称"公司"）全资子公司北京以岭药业有限公司（以下简称"北京以岭"） 独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保 险和工伤保险药品目录（2025 年）》（以下简称"《国家医保目录》（2025 版）"）。 具体情况如下： 一、芪防鼻通片进入医保情况 剂型：片剂 药品注册分类：中药 1.1 类 是否独家品种：是 药品分类及代码：鼻病 ZF02 医保支付标准：1.78 元（0.47g（相当于饮片 1.52g）/片） 协议有效期：2026 年 1 月 1 日至 2027 年 12 月 31 日 2、药品其 ...

Core Viewpoint - The National Medical Insurance Drug List for 2025 has been officially published, with Yiling Pharmaceutical's innovative drug Qifang Nizhong Pian being included for the first time [1] Group 1: Drug Approval and Market Entry - Qifang Nizhong Pian is an innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, addressing a clinical gap in medication [1] - The drug received approval from the National Medical Products Administration in January 2025 and was registered by the Macao Special Administrative Region's government on July 12, 2025, marking it as the first innovative traditional Chinese medicine approved in Macao [1]